Dec 09,2019 | Chugai’s Nemolizumab Receives FDA Breakthrough Therapy Designation for the Treatment of Pruritus Associated with Prurigo Nodularis | News | CHUGAI PHARMACEUTICAL CO., LTD.
www.chugai-pharm.co.jp